Recent share performance and business snapshot

Insulet (PODD) has drawn investor attention after a period of share price pressure, with the stock down 2.3% on the day and about 22% over the past month.

Over the past 3 months the stock has fallen about 42%, contributing to a year-to-date decline of nearly 50%. Against that backdrop, investors are reassessing the company’s fundamentals and current valuation.

Insulet generates US$2.9b in revenue and US$302.8m in net income, primarily from its Omnipod insulin delivery systems for people with insulin dependent diabetes, sold across the United States and international markets.

The recent share price decline, including a 7 day share price return down 9.1% and a 1 year total shareholder return down 56.0%, suggests sentiment has cooled as investors weigh Insulet’s earnings profile, growth record and current valuation.

If you are rethinking your healthcare exposure after Insulet’s slide, it could be a good moment to look at other growth stories using the 35 healthcare AI stocks.

With the stock under pressure and an indicated intrinsic discount of about 56%, plus a sizeable gap to the average analyst price target, you now have to ask: is Insulet mispriced, or is the market already factoring in future growth?

Most Popular Narrative: 56% Undervalued

Insulet's most followed narrative points to a fair value of $326.35 per share compared with the last close at $142.65, framing a large valuation gap for investors to assess.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.

Curious what sits behind that upside case? The narrative leans on faster revenue growth, rising profit margins and a future earnings multiple that assumes strong execution. See our AI narrative and valuation for Insulet.

Result: Fair Value of $326.35 (UNDERVALUED)

However, the story can change quickly if Omnipod faces tougher competition or pricing pressure, or if global expansion investments fail to earn adequate returns.

Another way to look at valuation

The narrative built around discounted cash flows suggests Insulet is trading well below an estimated fair value of about $327 per share, pointing to undervaluation. However, the stock changes hands at a P/E of 32.6x, which is higher than the US Medical Equipment industry at 24.3x and above its own fair ratio of 29.7x. How comfortable are you paying a richer multiple for a stock that screens cheap on cash flows?

Next Steps

With such a mixed picture on value and growth, sentiment can shift quickly. Consider reviewing the data yourself and weighing the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Insulet has you rethinking your watchlist, do not stop here. Use the Simply Wall St Screener to uncover fresh opportunities that fit your style before others do.

• Target stability first by reviewing companies in the 64 resilient stocks with low risk scores that may suit a more cautious approach to compounding wealth.
• Hunt for potential bargains by scanning the 46 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Spot lesser known opportunities by checking the screener containing 22 high quality undiscovered gems that could offer growth potential before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.